Table 1.
Trial summary table
| Group 1 | Group 2 | Group 3 | Group 4 | |
|---|---|---|---|---|
| N = 10 | N = 5 | N = 10 (N = 4 received CHMI) | N = 5 (N = 4 received CHMI) | |
| Dose (number of PfSPZ) | 3 × 75,000 | 0 | 3 × 75,000 (N = 2) | 0 |
| 4 × 75,000 (N = 8) | ||||
| Route of administration | ID | ID | ID | ID |
| Number of volunteers who became TS+ | 8 | 5 | N/A | N/A |
| Listing of times to TS+ (days) | 10.5, 10.5, 11, 12, 12, 14, 14.5, and 15 | 10.5, 10.5, 13.5, 14, and 16 | N/A | N/A |
| Geometric mean time to TS+ (days) | 13.7 | 12.7 | N/A | N/A |
| Listing of parasite density by qPCR at time of TS+ (parasites/μL blood) | 14, 26, 13, 40, 46, 66, 24, and 27 | 44, 120, 75, 32, and 1 | N/A | N/A |
| Geometric mean parasite density by qPCR at time of TS+ (parasites/μL blood) | 27.9 | 26.3 | N/A | N/A |
| Number of volunteers who became qPCR+ | 10 (100%) | 5 (100%) | 4 (100%) | 4 (100%) |
| Listing of times to qPCR+ (days) | 7.0, 7.0, 7.0, 7.0, 7.0, 7.0, 9.0, 10.5, 10.5, and 10.5 | 7.0, 7.0, 7.0, 7.0, and 10.5 | 7.0, 10.5, 10.5, and 10.5 | 7.0, 7.0, 7.0, and 10.0 |
| Geometric mean time to qPCR+ (days) | 8.1 | 7.6 | 9.5 | 7.7 |
| Listing of parasite densities by qPCR at time of qPCR+ (parasites/μL blood) | 0.08, 1.01, 0.09, 0.13, 0.25, 0.07, 0.08, 0.05, 0.05, and 0.08 | 1,02, 0.47, 0.90, 0.13, and 1.78 | 0.74, 1.40, 0.08, and 0.06 | 0.86, 0.36, 0.97, and 0.52 |
| Geometric mean parasite density by qPCR at time of qPCR+ (parasites/μL blood) | 0.11 | 0.63 | 0.27 | 0.63 |
CHMI = controlled human malaria infection; ID = intradermal; N/A = not applicable; PfSPZ = Plasmodium falciparum sporozoite; qPCR+ = quantitative real-time polymerase chain reaction positive; TS+ = thick smear positive.